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Abstract 28 
Background: Fatigue affects between 49 and 92% of dialysis patients with considerable 29 
repercussions on their functioning and quality of life.  30 
Purpose: To evaluate whether fatigue severity and its impact on functioning predict survival 31 
(all-cause mortality) and time to transplantation among in-centre haemodialysis patients. 32 
Methods: As part of a prospective study of fatigue among in-centre haemodialysis patients, 33 
survival data was collected between April 2014 and August 2017. Fatigue severity was 34 
measured using the Chalder Fatigue Questionnaire (CFQ) and fatigue-related functional 35 
impairment using the Work and Social Adjustment Scale (WSAS). Sociodemographic, clinical, 36 
and psychological data were collected. The association between fatigue and outcomes was 37 
assessed using proportional hazard survival models, allowing for competing risks, and discrete-38 
time survival models. All models were adjusted for relevant risk factors. 39 
Results: The sample consisted of 174 haemodialysis patients. There were 37 deaths and 31 40 
transplantations over 3 years. At 1095 days (36 months), cumulative survival was 70.5% and 41 
the cumulative transplantation rate was 22.2%. In unadjusted models, fatigue was significantly 42 
associated with an increased risk of death (CFQ-continuous SHR=1.06, 95% CI 1.02, 1.11; 43 
CFQ-dichotomous SHR=2.18, 95% CI 1.11, 4.31; WSAS SHR=1.03, 95% CI 1.01, 1.05) and 44 
decreased likelihood of transplantation (CFQ-continuous SHR=0.92, 95% CI 0.87, 0.98; CFQ-45 
dichotomous SHR=0.33, 95% CI 0.15, 0.75; WSAS SHR=0.96, 95% CI 0.93, 0.99). However, 46 
these associations ceased to be significant after controlling for covariates.  47 
Conclusions: Fatigue was predictive of an increased risk of death and decreased likelihood of 48 
transplantation among patients, possibly through distress, impaired functioning and its 49 
consequences, rather than clinical and inflammatory markers.  50 
Keywords: fatigue, vitality, dialysis, transplantation, survival, mortality, outcome 51 
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Introduction 57 
Chronic Kidney Disease (CKD) is a disease of the kidneys with progressive renal 58 
damage and loss in renal functioning that often progresses to kidney failure, when 59 
functioning of the kidneys drops to below 15ml/minute/1.73m² [1]. This is when renal 60 
replacement therapy is necessary to sustain life, in the form of dialysis or transplantation [1]. 61 
Haemodialysis is the most common form of renal replacement therapy, particularly at 62 
diagnosis [2], which involves an artificial extracorporeal blood circuit to remove wastes from 63 
the blood, fulfilling some essential functions of the kidneys [1]. A typical haemodialysis 64 
patient attends dialysis sessions three times a week for 3-4 hours each time [3]. In 2013, an 65 
estimated 22,570 patients were receiving in-centre haemodialysis in the UK [4].  Although, 66 
haemodialysis is life-sustaining, mortality rates still fluctuate at around 20% per year [5,6]. 67 
Kidney failure is characterised by a number of symptoms including: fatigue, pruritus, 68 
drowsiness, dyspnea, edema, pain, dry mouth, muscle cramps, restless leg syndrome, lack of 69 
appetite, poor concentration, dry skin, sleep disturbance, constipation, and sexual dysfunction 70 
[7,8]. On average, stage 5 patients, managed without dialysis, report experiencing 14 71 
symptoms [9].  72 
Fatigue is one of the most common and disruptive symptoms of kidney disease, 73 
affecting 42 to 89% of patients on renal replacement therapy, depending on the fatigue 74 
measurement tool used and treatment modality. [10]. Despite improvements in clinical care, 75 
fatigue remains a recurrent complaint of haemodialysis patients [11]. Fatigue is a complex 76 
and subjective symptom of distressing and persistent feeling of physical, emotional, and/or 77 
cognitive exhaustion and tiredness not proportional to exertion and not relieved by rest [12-78 
14].  79 
The consequences of fatigue are marked. Qualitative studies revealed that fatigue can 80 
impair dialysis patients’ ability to carry out basic activities, such as preparing a meal, can 81 
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affect motivation, and act as a barrier to participation in social activities; therefore, leading to 82 
social isolation [15-18]. The effects of fatigue on functioning are further exacerbated on 83 
dialysis days [15,16]. Multiple quantitative studies have shown that fatigue negatively 84 
impacts on functioning and quality of life [19-23], and contributes to poorer sleep quality and 85 
increased bodily pain [22-26]; however, these associations are likely to be bidirectional.  86 
Recent evidence suggests that fatigue also has implications on clinical outcomes 87 
[24,25,27]. There is evidence to suggest that fatigued haemodialysis patients have a 88 
significantly higher risk for cardiovascular events compared to their non-fatigued 89 
counterparts [27].  Furthermore, fatigue symtoms have been associated with increased 90 
mortality in dialysis patients [24,25,28]. The association between fatigue and mortality has 91 
also been previously documented in other long-term physical conditions, such as cancer and 92 
cardiovascular disease [29,30]. The underlying mechanisms and pathophysiology of the 93 
association between fatigue and mortality remain unclear, although a number of mechanisms 94 
have been proposed, including inflammation, malnutrition, and depression.  95 
Depression is common among haemodialysis patients, with an estimated prevalence 96 
between 20 and 30% [31-34]. Extensive evidence is also available on the association between 97 
depression and mortality across long-term physical conditions [35-37], including kidney 98 
failure [32,33,38-42]. Out of the studies that have examined the prognostic role of fatigue 99 
symptoms in this patient population [24,25,27,28], only Bossola et al. [28] considered the 100 
role of depression in the association between fatigue and mortality. They found that although 101 
some variance of the association between fatigue and mortality may be explained by 102 
depression, fatigue remained a significant predictor of mortality, independently from 103 
depression.  Other complex biopsychosocial relationships likely exist to help explain how 104 
fatigue can impact on clinical outcomes among haemodialysis patients. As postulated in a 105 
review [43], a number of fatigue triggers exist in this patient population, particularly 106 
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biomedical factors such as inflammation and fluid removed on dialysis. In turn,  thoughts, 107 
emotions, and behaviours in response to fatigue, and the illness more broadly, may maintain 108 
and perpetuate fatigue, leading to further biological consequences over time, such as 109 
deconditioning, disruption of the sleep-wake cycle, and physiological arousal. 110 
Additionally, to our knowledge, no studies have examined the association between 111 
fatigue and kidney transplantation.  [40,42]. 112 
 113 
Rationale 114 
Fatigue is often under-recognised and under-treated by healthcare professionals 115 
(HCPs), perceived as an inevitable consequence of the illness and treatment burden [44]. 116 
Therefore, there is a need to provide further evidence on the association between fatigue 117 
symptoms and outcomes, by replicating Bossola et al.’s [28] findings in a larger sample, 118 
whilst taking into account that in haemodialysis there are two possible competing events: 119 
death or transplantation; therefore, using traditional survival analysis is statistically 120 
inappropriate, resulting in the overestimation of risk of the event of interest [45,46]. 121 
Additionally, the contribution of fatigue-related interference to outcomes has not been 122 
previously explored. Further evidence regarding the association between fatigue and clinical 123 
outcomes may not only promote better recognition of fatigue as a serious problem in this 124 
patient population and therefore development of effective fatigue treatments, but also shed 125 
some light into the mechanisms by which fatigue may impact on clinical outcomes.    126 
Objective 127 
The aim of this prospective study was to evaluate whether fatigue severity and fatigue-128 
related functional impairment are predictive of outcome (mortality or transplantation) over a 129 
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three-year period, after controlling for known risk factors, such as age, comorbidity, C-130 
Reactive Protein (CRP), haemoglobin, albumin, and distress.  131 
We hypothesized that baseline levels of fatigue and fatigue over time would predict outcome, 132 
survival and time to transplantation, of haemodialysis patients over the study period. 133 
Methods 134 
Study design  135 
The current study utilises data from a prospective study of fatigue, in which patients 136 
completed various psychosocial questionnaires (outlined below) annually over 36 months 137 
[47]. The study ran between April 2014 and August 2017. Over the study period, mortality 138 
and transplantation events were recorded from medical records. The association between 139 
fatigue severity levels and fatigue-related functional impairment with these outcomes was 140 
evaluated here, with time-zero in the survival models being the date patients completed the 141 
baseline assessment.   142 
 The study was reviewed and received ethical approval from an NHS Research Ethics 143 
Committee (East Midlands-Leicester NRES committee, Reference number 14/EM/0037) and 144 
has received local Research and Development (R&D) approval. All participants provided 145 
written informed consent. The study adhered to the Declaration of Helsinki (1964) ethical 146 
standards.  147 
Participants  148 
The sample consisted of in-centre haemodialysis patients, receiving conventional three- 149 
to four-hour haemodialysis, three times a week. Patients were recruited from one specialised 150 
renal unit in the United Kingdom, and its associated satellite dialysis units. Adults (aged 18 151 
or older) with a confirmed kidney failure diagnosis, treated with in-centre haemodialysis, for 152 
90 days or longer, able to speak or write in English, and able and willing to provide informed 153 
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consent were considered eligible. Exclusion criteria were as follows: (i) significant visual or 154 
physical impairment preventing completion of the questionnaires, (ii) any known cognitive 155 
impairments, and (iii) serious mental health conditions as noted in the medial history (e.g. 156 
psychosis, personality disorder).  Patients were not approached if they were judged to be 157 
unsuitable by the nursing staff, repeatedly unwell during the recruitment period or in the 158 
process of moving to peritoneal dialysis. 159 
279 patients were approached for study participation, with 174 providing informed 160 
consent and completing the baseline questionnaires (62.4%). A patient recruitment flowchart 161 
is available elsewhere [47]. At 12 months 118 patients (87% of patients still alive, on dialysis, 162 
and able to complete the questionnaires) completed questionnaires, at 24 months 84 patients 163 
(98% of patients still alive, on dialysis, and able to complete the questionnaires) completed 164 
questionnaires, and at 36 months 66 patients completed questionnaires (99% of patients still 165 
alive, on dialysis, and able to complete the questionnaires). Please see the participant flow 166 
diagram for further detail on the study retention (Figure 1).  167 
 168 
Figure 1. Flow diagram of participants through the study. 169 
 170 
174 haemodialysis patients 
recruited into the study
At 12 months, 118  
completed the questionnaires
At 24 months, 84 completed 
the questionnaires
At 36 months, 66 completed 
the questionnaires
 
 
• 13 died 
• 18 were transplanted 
• 2 moved away 
• 5 were no longer receiving in-
centre haemodialysis 
• 18 dropped out from the study • 16 died 
• 12 were transplanted 
• 3 moved away 
• 1 was no longer receiving in-
centre haemodialysis 
• 2 dropped out from the study 
• 8 died 
• 1 was transplanted 
• 2 moved away 
• 4 were no longer receiving in-
centre haemodialysis 
• 1 dropped out from the study 
• 2 were in-patients during data 
collection 
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 171 
Demographic and clinical data collection  172 
The following sociodemographic and clinical data were recorded for each patient at 173 
baseline, using a self-report questionnaire: age, gender, marital status, employment status, 174 
ethnicity, living arrangements, current smoking status, exercise status, primary renal 175 
diagnosis, dialysis vintage (length of time on dialysis in months), access type, and perceived 176 
transplant list status.  177 
Comorbidity was assessed at baseline using the Charlson Comorbidity Index (CCI) 178 
[48]. The CCI is a weighted index that takes into account the number and the seriousness of 179 
comorbid diseases. The method of classifying comorbidity provides a simple, readily 180 
applicable and valid method of estimating risk of death from comorbid disease for use in 181 
longitudinal studies [48]. The CCI has been previously used in incident haemodialysis and 182 
peritoneal dialysis patients [49] and was found to be the most suitable instrument to predict 183 
patient survival in another study, compared to other comorbidity indices, like the Khan Index 184 
score [50]. It is also simpler to score, not requiring a trained person, as compared to the Index 185 
of Coexistent Disease.  186 
The following clinical and laboratory data were collected at each data collection time-187 
point from medical records: haemoglobin (Hb, g/dL), albumin (g/dL), creatinine (umol/L), urea 188 
(mmol/L), inter-dialytic weight loss (IDWL, Kg), C-Reactive Protein as a marker of 189 
inflammation (CRP, mg/L), dialysis adequacy (Urea Reduction Ratio, %), and Body Mass 190 
Index (BMI, kg/m2). EPO dose and related treatments for anaemia (iron) and transplant list 191 
status were also recorded. This clinical data is routinely collected as part of standard care.  192 
Psychological questionnaires  193 
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All psychological questionnaires were administered at baseline, 12, 24 and 36 months follow-194 
up.   195 
The Chalder Fatigue Questionnaire [51]. This instrument was used to measure fatigue 196 
severity. It consists of 11 items. Scores are assigned for each response, using continuous 197 
scoring from 0 to 3. A cut-off of greater than 18 defines a fatigue case, using the continuous 198 
scoring [51,52]. A composite of the item scores represents fatigue severity. Higher scores 199 
represent greater fatigue severity. The composite score will be used here following recent 200 
psychometric evidence [53,54]. Cronbach’s alpha for this scale was reported at α=0.89, 201 
representing excellent reliability [51], as well as demonstrating discriminant validity [51] and 202 
sensitivity to change [55]. In this sample, Cronbach’s alpha was α=0.91. The CFQ has been 203 
used across a range of chronic illnesses to measure fatigue [56-58]. It has also been 204 
previously used and validated with renal patients [59,60]. 205 
Work and Social Adjustment Scale (WSAS)[61]. This instrument was used to measure 206 
fatigue-related functional impairment. It consists of five items that correspond to impairment 207 
in work, home management, social activities, private leisure activities and relationships as 208 
consequence of an illness or symptom, in this case fatigue. Higher scores indicate greater 209 
impairment. It has good psychometric properties, underlined by satisfactory Cronbach's α, 210 
ranging from 0.70 to 0.94 [61]. In this sample, Cronbach’s alpha was α=0.94. 211 
Hospital Anxiety and Depression Scale (HADS)[62]. This instrument is widely used for 212 
assessing depression and anxiety in patients with medical illnesses [62]. This instrument 213 
measures anxiety and depression via a 14-items scale, with 7 items pertaining to anxiety and 214 
7 to depression. Each item is scored from 0-3, with a range from 0 to 21, 21 for severe 215 
anxiety or depression. A total score for distress can also be computed, ranging from 0 to 42, 216 
again with higher scores reflecting greater distress. A total score appears to be more 217 
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appropriate in kidney failure [63]. A review of the HADS found consistent support of its 218 
psychometric properties across samples, with an average Cronbach’s alpha for HADS-A of 219 
α=0.83, and for HADS-D of α=0.82 [64]. In this sample, Cronbach’s alpha for the combined 220 
subscales was α=0.90 (HADS-A α=0.85 & HADS-D α=0.80). This scale has been 221 
consistently used in kidney failure, performing well within this patient population [63,65].  222 
Statistical analysis  223 
Sample characteristics were summarised using descriptive statistics. To compute 224 
questionnaire scores, scores on items were added together with prorating of missing scores, 225 
with a conservative threshold of at least 50% of items on a questionnaire being completed 226 
(i.e. 6 out of 11 items on the CFQ)[66]. This method of handling item-level missing data is 227 
acceptable when a high proportion of the items (never fewer than half) are used to inform the 228 
total score, the item-total correlations are similar, and the internal consistency of the scale is 229 
high [66]. Therefore, it was deemed appropriate here.  230 
In this patient population, there are two competing risks: death or transplantation. A 231 
transplant is a competing risk because after the transplantation, dialysis is no longer 232 
necessary; therefore, this eliminates the risk of dying while being on dialysis, while a 233 
transplant is no longer possible for someone who has died [45]. Patients were censored if they 234 
changed dialysis modality, moved away, were hospitalised during the data collection period, 235 
or dropped out. Univariate associations between sociodemographic, clinical and 236 
psychological variables with events were examined using bivariate correlations (Pearson or 237 
Spearman depending on normal distribution of the data) for continuous variables; ANOVA 238 
comparisons for normally distributed categorical variables according to survival status or the 239 
nonparametric Kruskal-Wallis H test; and the two-tailed Fisher exact test was used for 240 
dichotomous variables.  241 
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Missing data were present in the dataset, with approximately 10.9% and 18.4% of 242 
observations missing in the mortality and transplantation models, respectively. Data were 243 
missing at random, based on exploratory data analysis. Multiple imputations were conducted, 244 
according to Sterne, White, Carlin, Spratt, Royston, Kenward, Wood, Carpenter 67]; using 20 245 
imputations and including variables in the model associated with missingness, such as total 246 
time in the study and censoring indicators. Competing risk survival models were estimated 247 
using the multiply imputed dataset.  248 
To estimate the cumulative incidence of survival, while taking into account the 249 
presence of the competing transplantation event and vice-versa, the cumulative incidence 250 
competing risk (CICR) method was used [46]. To correctly estimate the probability of the 251 
events of interest, without over-inflation, analyses need to account for the competing risk 252 
[46].  253 
To explore the effect of baseline fatigue severity, as a continuous score or a binary 254 
category (fatigued vs. non-fatigued using the aforementioned cut-off), and baseline fatigue-255 
related functional impairment  on events (mortality or transplantation), while accounting for 256 
the presence of competing events, the subdistribution hazards approach was used here [68].  257 
The models with death as the event of interest were adjusted for: age at baseline, 258 
gender, ethnicity (white versus non-white), comorbidities at baseline (CCI, Charlson 259 
Comorbidity Index), dialysis vintage at baseline (months), transplant list status at baseline (fit 260 
versus unfit), intradialytic weight loss at baseline (IDWL, Kg), blood haemoglobin at 261 
baseline (g/L), serum albumin at baseline (g/L), history of cardiovascular disease (yes versus 262 
no), and distress at baseline (HADS). For time to transplantation, the following covariates 263 
were controlled for: age at baseline, gender, ethnicity (white versus non-white), employment 264 
status (working versus not working) at baseline, BMI at baseline, comorbidities at baseline 265 
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(CCI, Charlson Comorbidity Index), dialysis vintage at baseline (months), transplant list 266 
status at baseline (fit versus unfit), intradialytic weight loss at baseline (IDWL, Kg), blood 267 
haemoglobin at baseline (g/L), serum albumin at baseline (g/L), serum creatinine at baseline 268 
(umol/L), serum urea at baseline (mmol/L), history of cardiovascular disease (yes versus no), 269 
exercise status at baseline (yes versus no), and distress at baseline (HADS). Models were 270 
adjusted in steps, by sociodemographic, clinical, and self-report psychological variables, to 271 
observe their individual impact on the association between fatigue and the event of interest. 272 
These variables were selected based on previous research identifying them as known risk-273 
factors of death and/or transplantation in this patient population, such as history of 274 
cardiovascular disease, and their univariate associations with the events in here.  275 
Given the considerable overlap between transplant list status and transplantation 276 
events, as part of sensitivity analysis, the models looking at transplantation were rerun using 277 
subgroups of patients deemed as fit for a transplant (patients active on the transplant list or 278 
working up) and those deemed not currently fit (patients unfit temporarily, unfit permanently, 279 
and suspended). 280 
Up to date CRP data were only available in a subsample of patients, since it is not 281 
routinely measured. Models were rerun with patients where CRP data were available at 282 
baseline, controlling for CRP, dichotomised into low (<5 mg/L) and high (>5 mg/L) based on 283 
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) 284 
clinical guidelines; in addition to the aforementioned covariates.  285 
Owing to the repeated data collection over time, discrete-time survival analysis, 286 
where time is divided into discrete chunks, were also conducted to explore the contribution of 287 
time-varying fatigue severity, with up to three repeated measures per patient over the 3-year 288 
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cohort time measured at yearly intervals, to the presence of the event of interest, death or 289 
transplantation, at each follow-up [69].  290 
Descriptive statistics and exploratory statistics were conducted in SPSS version 23.0. 291 
Survival analyses were conducted in STATA, using the stcurve, cif and the stcrreg 292 
commands [70] to apply the CICR method [46]. Effects are expressed as subdistribution 293 
hazard ratios (SHRs) with 95% confidence intervals (CI). Data were converted from wide to 294 
long format and set as longitudinal (xtset [71]) before using the cloglog command [72] to 295 
estimate discrete-time survival models. Effects of discrete-time survival models are expressed 296 
as hazard ratios (HRs) with 95% confidence intervals (CI). Significance was set at p≤0.05, 297 
using the standard α cut-off. To account for multiple tests resulting from treating fatigue as a 298 
continuous or binary variable or looking at fatigue-related functional impairment, an adjusted 299 
p-value cut-off of p=0.02 was also used, based on the Bonferroni correction (0.05/3=0.02). 300 
Results 301 
Sample characteristics 302 
The sample consisted of 174 patients receiving in-centre haemodialysis. Demographic 303 
and clinical characteristics of the sample have been previously described elsewhere [47]. 304 
Most of the sample was male (63.2%) with a mean age of 59.0 years old (SD=15.2). The 305 
median dialysis vintage was 34.5 months (interquartile range=52). At baseline, mean fatigue 306 
was 17.34 (95% CI 16.36-18.32) and 82 patients (47.1%) could be deemed as suffering from 307 
clinical fatigue, scoring 18 or above on the CFQ. At baseline, the mean fatigue-related 308 
functional impairment score was 18.5 (SD=13.0). 309 
CRP at baseline was available in 82.2% of the sample (N=143), with 56.3% classed as 310 
having high CRP (> 5 mg/L). There were no significant differences in fatigue severity scores 311 
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between patients with high CRP versus those with low CRP, or the proportion deemed 312 
fatigued (CFQ >18).  313 
Outcomes characteristics 314 
During the three-year follow-up period, there were 37 deaths and 31 transplantations. 315 
The estimated median survival time and time to transplantation could not be reported because 316 
the events were not observed for >50% cases. Cumulative survival at 1095 days (36 months) 317 
was 70.5%. The cumulative transplant event rate at 1095 days (36 months) was 22.2%. 318 
Censorship events included: drop-out (N=21), switching dialysis modality (N=10), transfer to 319 
a different hospital (N=7), and hospital admission (N=2). 320 
Mortality and transplantation by fatigue 321 
The mean estimated survival time for death as the event of interest was longer among 322 
patients deemed not fatigued (mean=987.93 days, standard error=30.72) compared to their 323 
fatigued counterparts (mean 896.29 days, standard error=39.06). When looking at 324 
transplantation events, the mean estimated survival time was longer among fatigued patients 325 
(mean=1012.23 days, standard error=30.99) versus not fatigued ones (mean=870.09 days, 326 
standard error=40.38). However, given the presence of competing risk, these estimates are 327 
inaccurate and cumulative incidence functions (CIFs) were estimated instead for death and 328 
transplantation events depending on fatigue status, based on the observed data (172 329 
observations, with 1.1% missing). According to Figure 2, fatigued patients were more likely 330 
to die over the course of the study compared to their not fatigued counterparts (SHR=2.28, 331 
95% CI 1.15 to 4.55, p=0.019). While, Figure 3, displays the CIF for transplantation events, 332 
where fatigued patients were less likely to receive a transplant over the course of the study 333 
(SHR=0.33, 95% CI 0.15 to 0.75, p=0.008). 334 
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335 
Figure 2. Cumulative incidence of death by fatigue status (not fatigued versus fatigued). 336 
 337 
Figure 3. Cumulative incidence of transplantation by fatigue status (not fatigued versus 338 
fatigued). 339 
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Competing risk subdistribution hazard models: Association of fatigue with mortality, taking 340 
into account the competing transplantation event 341 
In the unadjusted model, fatigue severity, treated both as a continuous or as a 342 
dichotomous variable, based on a score cut-off of ≥18; was significantly associated with an 343 
increased risk of mortality (Table 1). A one point increase in fatigue severity was associated 344 
with a 6% increase in the risk of death among patients who are alive or who have been 345 
transplanted (p=0.002, 95% CI 1.02 to 1.11). Fatigue as a clinical cut-off score was 346 
associated with a 2.18 times increase in the risk of death (p=0.02; 95% CI 1.11 to 4.31). The 347 
association between fatigue severity as a continuous variable and mortality ceased to be 348 
significant after controlling for distress (HADS)(Table 1). However, fatigue as a dichotomous 349 
variable was no longer a significant predictor of mortality, after controlling for clinical 350 
factors, which is likely due to reduced power (Table 1).  A one point increase in fatigue-351 
related functional impairment was associated with a 3% increase in the risk of death 352 
(p=0.005, 95% CI 1.01 to 1.05). This association remained significant after adjusting for 353 
sociodemographic and clinical variables, and it was marginally significant after controlling 354 
for distress (p=0.056)(Table 1).355 
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Table 1 356 
Association between Fatigue and Mortality: Subdistribution Competing Risks Models (N=174) 357 
 Competing Risk Subdistribution Hazard Models (SHRs and 95% CI) 
 Model 1: unadjusted Model 2: adjusted for 
sociodemographic variablesa 
 
Model 2: adjusted for 
sociodemographic and clinical 
variablesb 
Model 3: adjusted for 
sociodemographic and clinical 
variables, and distressc 
CFQ (continuous) 1.06†‡ (1.02, 1.11) 1.06†‡ (1.02, 1.11) 1.06†‡ (1.01, 1.10) 1.05 (0.99, 1.12) 
 
CFQ ≥ 18 2.18† (1.11, 4.31) 2.15† (1.10, 4.23) 1.94 (0.95, 3.96) 1.77 (0.81, 3.89) 
 
WSAS 1.03†‡ (1.01, 1.05) 1.03†‡ (1.01, 1.06) 1.03†‡ (1.01, 1.06) 1.03 (1.00, 1.07) 
a Model adjusted for age, gender, and ethnicity (white versus non-white). 358 
b Model adjusted for age, gender, and ethnicity (white versus non-white), comorbidities using the Charlson Comorbidity Index score, dialysis vintage, 359 
intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), haemoglobin (g/L), and history of cardiovascular disease (yes versus 360 
no). 361 
c Model adjusted for age, gender, and ethnicity (white versus non-white), comorbidities using the Charlson Comorbidity Index score, dialysis vintage, 362 
intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), haemoglobin (g/L), history of cardiovascular disease (yes versus 363 
no), and distress (HADS total score). 364 
SHR=subdistribution hazard ratio, CI=confidence interval 365 
†p<0.05 366 
‡p<0.02; Bonferroni-corrected 5% alpha level 367 
 368 
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Competing risk subdistribution hazard models: Association of fatigue with transplantation, 369 
taking into account the competing mortality event 370 
Similarly, fatigue severity, treated both as a continuous and as a dichotomous variable 371 
was significantly associated with a decreased likelihood of transplantation, in the unadjusted 372 
models (Table 2). A one-point increase in fatigue severity was associated with an 8% 373 
reduction in the likelihood of transplantation among patients who are alive or who have died 374 
(p=0.009, 95% CI 0.87 to 0.98). In those who did not experience the event of interest 375 
(transplantation) or a competing event (death), a change in fatigue status (not fatigued to 376 
fatigued), was associated with a 67% reduction in the odds of receiving a transplant (p=0.008, 377 
95% CI 0.15 to 0.75). The association between fatigue severity, as a continuous variable, 378 
ceased to be significant after controlling for sociodemographic variables, including 379 
employment status, while fatigue status remained significant until clinical variables were 380 
added to the model (Table 2). Fatigue-related functional impairment was a significant 381 
predictor of a 4% reduction in the likelihood of transplantation (p=0.013, 95% CI 0.93 to 382 
0.99), until sociodemographic factors were added to the model. The effect of fatigue on the 383 
likelihood of transplantation was further attenuated when exercise status was added to the 384 
models (Table 2).  385 
Similar findings were obtained when looking at the association of fatigue symptoms 386 
with transplantation events in a subsample of patients who were active on the transplant list 387 
or working up and in a subsample of patients who were deemed currently unfit for a 388 
transplant (Appendix A). There was no indication for an attenuation of the effect of fatigue 389 
severity on transplantation when controlling for distress (SHR=0.93, p=0.019, 95% CI 0.87 to 390 
0.99), while the effect of fatigue severity became non-significant after controlling for 391 
employment status (SHR=0.94, p=0.089, 95% CI 0.88 to 1.01). Adding BMI to this model 392 
attenuated the effect of fatigue severity only slightly further (SHR=0.95, p=0.164, 95% CI 393 
0.89 to 1.02). The effect of employment status on the likelihood of transplantation ceased to 394 
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be significant after controlling for transplant list status. The same pattern was observed with 395 
fatigue-related functional impairment.  396 
Competing risk subdistribution hazard models: CRP subgroup analysis 397 
 In the subgroup analysis, where CRP data were available, there was no evidence for 398 
an attenuation of the effect of fatigue and fatigue-related functional impairment on neither 399 
mortality nor transplantation, in the adjusted models (Table 3).400 
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Table 2 401 
Association between Fatigue and Transplantation: Subdistribution Competing Risks Models (N=174) 402 
 Competing Risk Subdistribution Hazard Models (SHRs and 95% CI) 
 Model 1: 
unadjusted 
Model 2: adjusted 
for 
sociodemographic 
variablesa 
Model 2: adjusted for 
sociodemographic and 
clinical variablesb 
Model 3: adjusted for 
sociodemographic and 
clinical variables, and 
exercise statusc 
Model 4: adjusted for 
sociodemographic and 
clinical variables, exercise 
status, and distressd 
CFQ (continuous) 0.92†‡ (0.87, 0.98) 0.94 (0.88, 1.01) 0.96 (0.89, 1.04) 0.97 (0.89, 1.05) 0.94 (0.86, 1.03) 
  
CFQ ≥ 18 0.33†‡ (0.15, 0.75) 0.36†‡ (0.15, 0.85) 0.50 (0.19, 1.37) 0.51 (0.17, 1.51) 0.28 (0.07, 1.21) 
 
WSAS 0.96†‡ (0.93, 0.99) 0.97 (0.94, 1.00) 0.98 (0.95, 1.02) 0.99 (0.95, 1.03) 0.96 (0.90, 1.03) 
a Model adjusted for age, gender, ethnicity (white versus non-white), and employment status (working versus not working). 403 
b Model adjusted for age, gender, ethnicity (white versus non-white), employment status (working versus not working), Body Mass Index (BMI), comorbidities 404 
using the Charlson Comorbidity Index score, dialysis vintage, intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), 405 
creatinine (umol/L), haemoglobin (g/L), urea (mmol/L), and history of cardiovascular disease (yes versus no). 406 
c Model adjusted for age, gender, ethnicity (white versus non-white), employment status (working versus not working), Body Mass Index (BMI), comorbidities 407 
using the Charlson Comorbidity Index score, dialysis vintage, intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), 408 
creatinine (umol/L), haemoglobin (g/L), urea (mmol/L), history of cardiovascular disease (yes versus no), and exercise status (yes versus no). 409 
d Model adjusted for age, gender, ethnicity (white versus non-white), employment status (working versus not working), Body Mass Index (BMI), comorbidities 410 
using the Charlson Comorbidity Index score, dialysis vintage, intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), 411 
creatinine (umol/L), haemoglobin (g/L), urea (mmol/L), history of cardiovascular disease (yes versus no), exercise status (yes versus no), and distress (HADS 412 
total score). 413 
SHR=subdistribution hazard ratio, CI=confidence interval 414 
†p<0.05 415 
‡p<0.02; Bonferroni-corrected 5% alpha level416 
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Table 3 417 
Association between Fatigue and Outcomes (Mortality or Transplantation): Subdistribution Competing Risks Models Adjusted for CRP (N=143) 418 
 Competing Risk Subdistribution Hazard Models (SHRs and 95% CI) 
 Mortalitya Transplantationb 
CRP-adjusted sub-analysis (N=143) 
CFQ (continuous)  1.05 (0.98, 1.13)  0.93 (0.80, 1.09) 
CFQ ≥ 18 1.91 (0.70, 5.25) 0.11† (0.01, 0.92) 
WSAS 1.04 (0.99, 1.09) 0.95 (0.86, 1.05) 
a Model adjusted for age, gender, and ethnicity (white versus non-white), comorbidities using the Charlson Comorbidity Index score, dialysis vintage, 419 
intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), haemoglobin (g/L), CRP (low versus high), history of cardiovascular 420 
disease (yes versus no), and distress (HADS total score). 421 
b Model adjusted for age, gender, ethnicity (white versus non-white), employment status (working versus not working), Body Mass Index (BMI), comorbidities 422 
using the Charlson Comorbidity Index score, dialysis vintage, intradialytic weight loss (IDWL, Kg), transplant list status (fit versus unfit), albumin (g/L), 423 
creatinine (umol/L), haemoglobin (g/L), urea (mmol/L), CRP (low versus high), history of cardiovascular disease (yes versus no), exercise status (yes versus 424 
no), and distress (HADS total score). 425 
SHR=subdistribution hazard ratio, CI=confidence interval 426 
†p<0.05 427 
‡p<0.02; Bonferroni-corrected 5% alpha level428 
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Discrete-time survival models: Association of time-varying fatigue with mortality & 429 
transplantation 430 
According to the time-dependent models based on the observed data, fatigue severity, 431 
treated as a continuous time-varying variable, was associated with an increased risk of death 432 
at each subsequent follow-up, but this association displayed only a trend towards significance 433 
in the unadjusted model (HR=1.04, 95% CI 1.00 to 1.08, p=0.08). In contrast, fatigue-related 434 
functional impairment over time was associated with a 3% increase in the risk of death at 435 
each subsequent follow-up (95% CI 1.00 to 1.05, p=0.022), but this association was no longer 436 
significant after controlling for time-varying distress (p=0.102). 437 
Conversely, fatigue severity over time was not a significant predictor of a 6% 438 
reduction in the likelihood of being transplanted at each subsequent follow-up, in the 439 
unadjusted time-dependent model (HR=0.94, 95% CI 0.88 to 1.00, p=0.04). Similarly, 440 
fatigue-related functional impairment over time was associated with a significant reduction in 441 
the odds of receiving a transplant at each subsequent follow-up (HR=0.96, 95% CI 0.93 to 442 
0.99, p=0.008). However, the associations between fatigue predictors and transplantation 443 
ceased to be significant when controlling for sociodemographic factors, including age (time-444 
varying), gender, ethnicity (white versus non-white), and employment status at baseline 445 
(working versus not working).  446 
Detectable effect size 447 
Based on the data here, detectable effect sizes were estimated to guide how 448 
underpowered the study may have been. The figures below relate to fatigue severity as a 449 
dichotomous variable: fatigued versus non-fatigued; which has the lowest power.  450 
A study with the same proportion of fatigued individuals followed for 3 years, with an 451 
annual incidence rate for death of 7% in non-fatigued individuals, would be able to detect a 452 
Author accepted version: Fatigue and clinical outcomes: survival analysis 
23 
 
population hazard ratio of at least 2.34 with 80% power at the 5% significance level. While, a 453 
study with the same proportion of fatigued individuals followed for 3 years, with an 454 
annual incidence rate for transplant of 20% in non-fatigued individuals, would be able to 455 
detect a population hazard ratio of at most 0.47 with 80% power at the 5% significance level. 456 
 457 
Discussion 458 
The aim of this paper was to assess the association between fatigue severity and 459 
fatigue-related functional impairment with all-cause mortality and kidney transplantation. 460 
This exploration was embedded in a longitudinal study of fatigue and its biopsychosocial 461 
correlates in haemodialysis. In this study, 47.1% of patients could be deemed clinically 462 
fatigued. This estimate is in line with previous estimates, suggesting that the prevalence of 463 
fatigue in this patient population ranges from 42% to 92% [7,10]. Therefore, approximately 464 
one in two patients suffer from clinical levels of fatigue, which only further accentuates the 465 
pervasiveness of fatigue symptoms among prevalent in-centre haemodialysis patients.  466 
Although, there appeared to be no direct association between fatigue and neither death 467 
nor transplantation after controlling for covariates; in the unadjusted models, fatigue severity 468 
and fatigue-related functional impairment were predictive of an increased risk of death and 469 
decreased likelihood of transplantation. In unadjusted models, a one-point increase in fatigue 470 
severity was associated with a 6% increase in the risk of death, and a change in fatigue status 471 
(not fatigued to fatigued) was associated with 2.18 times increase in the risk of death. The 472 
association between fatigue severity and mortality ceased to be significant after controlling 473 
for distress, suggesting that fatigue severity may impact on survival indirectly through mood, 474 
rather than through clinical factors. Fatigue-related functional impairment was associated 475 
with a 3% increase in the risk of death and this association remained marginally significant 476 
Author accepted version: Fatigue and clinical outcomes: survival analysis 
24 
 
and was not attenuated by distress, suggesting that the impact of fatigue on daily roles may be 477 
particularly detrimental for survival. 478 
On the other hand, in the unadjusted models, a one-point increase in fatigue severity 479 
was associated with an 8% reduction in the likelihood of receiving a transplant, and a change 480 
in fatigue status (not fatigued to fatigued) was associated with a 67% reduction in the odds of 481 
receiving a transplant. A similar effect was observed with fatigue-related functional 482 
impairment. In adjusted models, the association between fatigue severity and fatigue-related 483 
functional impairment with transplantation ceased to be significant when controlling for 484 
sociodemographic covariates, including employment status, possibly acting as a marker of 485 
functioning. On the other hand, the association between fatigue status and transplantation 486 
ceased to be significant after controlling for clinical variables, suggesting that fatigue may 487 
indirectly reduce the likelihood of getting a transplant, by increasing BMI and consequently 488 
being considered less fit for a transplant. This disparity between fatigue severity as a 489 
continuous or dichotomous predictor may be indicative of the exacerbated influence of 490 
clinical levels of fatigue on the likelihood of transplantation. In contrast to the models 491 
looking at death, there was no evidence for an attenuation of the effect between fatigue and 492 
transplantation when controlling for distress, but only after controlling for functioning-related 493 
factors. 494 
Similarly, according to the discrete-time survival models, fatigue severity and fatigue-495 
related functional impairment over the study period were predictive of a 6% and 4% 496 
reduction in the likelihood of being transplanted at each subsequent follow-up, respectively, 497 
but this effect became non-significant after controlling for sociodemographic covariates. 498 
However, this temporal association was not observed between time-varying fatigue severity 499 
and mortality. Only fatigue-related functional impairment over time was predictive of 500 
mortality at each subsequent follow-up, but this ceased to be significant after controlling for 501 
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distress. There was no evidence for an attenuation of the effect of fatigue on neither mortality 502 
nor transplantation when controlling for inflammation.  503 
Previous Research 504 
Past research has shown the prognostic value of fatigue in predicting mortality across 505 
different patient populations [29,30,73-75], including dialysis patients [24,25,28]. In a study 506 
of breast cancer patients, higher levels of fatigue were associated with a shorter recurrence-507 
free survival time, after controlling for clinical and treatment-related covariates [29]. 508 
Furthermore, in the general population, being in the highest quartile of fatigue was associated 509 
with a 26% increase in all-cause mortality risk, after adjusting for known risk factors [76].  510 
Similarly, there is evidence for the association between fatigue and all-cause mortality 511 
among dialysis patients [24,25,28]. For example, survival of patients who reported a decline 512 
in vitality at one year follow-up was 3.0 years versus 3.8 years in patients whose vitality was 513 
stable or improved [24]. In another study, a one-unit increase in vitality was associated with a 514 
1.00% increase in mean survival [25]. This is in contrast to the findings here, where no 515 
significant direct association between fatigue severity and mortality was identified in adjusted 516 
models.  Similarly, Koyama et al. failed to find a significant association between fatigue and 517 
all-cause mortality, yet fatigue was predictive of cardiovascular events among haemodialysis 518 
patients [27]. This disparity in findings may stem from differences in measurement of fatigue 519 
and looking at all-cause versus cause-specific mortality, suggesting that the association 520 
between fatigue and mortality is likely to be complex and multifaceted. To date, the 521 
association between fatigue and transplantation has not been investigated and it is yet to be 522 
established whether fatigue is a risk factor for mortality or graft rejection among kidney 523 
transplant recipients [77].  524 
Underlying Mechanisms 525 
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Understanding the mechanisms at play in the association between fatigue and clinical 526 
outcomes is currently tentative at best. Potential mediators of the association between fatigue 527 
and mortality that have been proposed in the literature, include increased treatment non-528 
adherence [78], deconditioning [28,79], malnutrition [25], and in particular increased 529 
inflammatory processes [80,81], possibly partially through depression [79,81]. For example, 530 
Jhamb et al. [25] found that a 1 g/dl increase in albumin was associated with an increase in 531 
vitality score by 7.7 points and 21% decrease in mortality risk. In kidney failure, 532 
inflammatory cytokines may contribute to pathological processes leading to cardiovascular 533 
disease (CVD) and mortality [82-85]. In fact, there is some evidence to suggest that increased 534 
inflammation may be one mechanism through which depression may exert a negative 535 
influence on survival [41,86]. Similar mechanisms may operate between fatigue and clinical 536 
outcomes, yet there was no evidence for this here. A large study in the general population 537 
found that the association between fatigue and mortality was particularly driven by CVD-538 
related deaths and this association was attenuated after adjusting for thyroid function and 539 
inflammation [76]. Furthermore, among haemodialysis patients, both depression and 540 
interleukin-6, an inflammatory cytokine, have been found to be significantly and 541 
independently associated with fatigue [81]. In fact, the association between fatigue severity 542 
and mortality was attenuated and ceased to be significant when controlling for distress, in 543 
contrast to Bossola et al.’s findings [28]. Yet, fatigue-related functional impairment remained 544 
marginally significant, indicating that perceived limitations in daily functioning as a result of 545 
fatigue may be particularly harmful. 546 
The mechanisms through which fatigue may contribute to a reduced likelihood of 547 
receiving a transplant remain elusive, but they are likely to be complex, including 548 
physiological and behavioural mediators. Approximately half of  people with kidney failure 549 
are suitable to receive a kidney transplant [87,88], following a comprehensive evaluation 550 
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based on criteria such as age below 75, a BMI of 35 or lower, and without an ongoing 551 
infection or severe heart disease [88,89]. Elevated levels of pro-inflammatory cytokines are 552 
therefore also likely to play a mediating role in the association between fatigue and 553 
transplantation; however, according to the findings here, controlling for CRP did not 554 
attenuate the association between fatigue and transplantation in the subgroup analysis. 555 
Similarly, there was no evidence for distress playing a role in the association between fatigue 556 
and transplantation. It is important to note that many factors come into play in 557 
transplantation, including availability of organs.  558 
The association between fatigue and transplantation appeared to be primarily driven 559 
by functioning-related factors. However, it is important to note that the relationship between 560 
fatigue and functioning is likely to be bidirectional. A consequence of the association 561 
between fatigue and reduced functioning may be increased BMI, possibly leading to 562 
transplant ineligibility. In fact, the association between fatigue and transplantation was 563 
attenuated and became non-significant when controlling for sociodemographic covariates, 564 
particularly employment status; clinical covariates, including BMI and transplant list status 565 
(fit versus unfit); and exercise status. Similarly to depression, fatigue may also lead to 566 
treatment non-adherence, which can impact on the assessment of suitability to receive a 567 
kidney transplant, but also following transplantation, it may lead to graft failure. This, in fact, 568 
has been documented when looking at depressive symptoms [90]. Lastly, some variance of 569 
the association between fatigue and transplantation may be explained by depression, as 570 
previous research has found that depression significantly reduces the odds of being on the 571 
transplant waiting-list [91], although it does not appear to be a risk factor for transplantation 572 
[41,91], as also found here. 573 
Overall, if we consider employment status, exercise status, and fatigue-related 574 
functional impairment as tapping into functioning, there is an indication that fatigue severity 575 
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may stop patients from doing things which may then have a detrimental impact on their 576 
overall functioning, consequently leading to poorer outcomes. This serves to further illustrate 577 
the complex biopsychosocial processes at play in the relationship between fatigue and clinical 578 
outcomes.  579 
Limitations of the Current Study and Future Directions 580 
The strengths of the study include the use of the Chalder Fatigue Questionnaire - a 581 
fatigue-specific scale displaying excellent psychometric properties, in contrast to the vast 582 
majority of previous research that has relied on the vitality subscale of the SF-36, possibly 583 
failing to capture every aspect of the fatigue experience [43]; evaluating the contribution of 584 
fatigue-related functional impairment; controlling for functioning-related factors and distress 585 
in the models; and looking at both mortality and transplantation events in proportional hazard 586 
survival models, allowing for competing risks.  587 
However, several limitations need to be acknowledged. Firstly, although the sample 588 
consisted of 174 patients at baseline, this may be insufficient to detect the effect of fatigue on 589 
outcomes. Additionally, only 62% of patients who were approached for participation, 590 
provided informed consent and completed the questionnaires, highlighting the risk of non-591 
response bias, possibly where the most fatigued patients were less likely to participate. 592 
However, the fatigue scores ranged from 0 to 33, suggesting that the severe-end of fatigue 593 
was captured in the data. Additionally, cause-specific mortality was not evaluated, which 594 
may have led to the null-effect of fatigue on mortality events in the adjusted models. The 595 
evidence is currently mixed with regards to the association between fatigue with cause-596 
specific mortality, such as cardiac events, or all-cause mortality [24,25,27]. Therefore, it 597 
would be valuable for future research to examine the predictive role of fatigue on cause-598 
specific mortality and transplantation in a larger sample, to determine the subtle nuances 599 
between these associations.  600 
Although important indicators of SES: ethnicity, employment status and years of 601 
education, were collected at baseline, data on income was not gathered. There is extensive 602 
evidence on the association between socio-economic status (SES) and mortality [92]; 603 
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therefore, the lack of a commonly used measure of SES is another limitation of this study. 604 
According to recent evidence, SES may act as a moderator of the effects of diabetes, 605 
hypertension, and obesity on the risk of death from renal disease [93]; therefore, complex 606 
non-linear relationships are likely at play. The sample was also limited to English-speaking 607 
patients, limiting generalizability. Although the sample was not predominantly white (43.1% 608 
white; 56.9% non-white) and a number of ethnicities were represented in the sample; a crude 609 
categorization into white versus non-white was used in the analyses, due to the low frequency 610 
of some ethnicities (e.g. one Chinese patient). There is evidence to suggest an interaction 611 
effect of depression and ethnicity on mortality events [39,94]; similar complex relationships 612 
may exist with fatigue; therefore, it would be valuable for future research to explore the 613 
interaction between fatigue and ethnicity on outcomes.  614 
 615 
Conclusion 616 
Despite the pervasive and incapacitating nature of fatigue in haemodialysis, it is often 617 
perceived as a normal consequence of the illness and treatment with little support provided 618 
for fatigue to patients. This study assessed the association between fatigue and clinical 619 
outcomes, specifically mortality and transplantation. Clinical levels of fatigue and elevated 620 
interference afforded by fatigue on life roles were common in the sample and were 621 
significantly associated with an increased risk of mortality and a reduction in the odds of 622 
transplantation in the unadjusted models. Furthermore, fatigue appeared to act as an 623 
antecedent predictor of an increased risk of mortality and reduced likelihood of 624 
transplantation at each subsequent follow-up. After adjusting for known risk factors, these 625 
associations ceased to be significant, suggesting that fatigue may impact on outcomes 626 
indirectly, through distress, reduced functioning and its clinical consequences, rather than 627 
clinical and inflammatory markers. The underlined mechanisms of the association between 628 
fatigue and outcomes are yet to be fully defined, but they are likely to be complex, including 629 
both physiological and behavioural mediators. The link between fatigue and clinical 630 
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outcomes only further accentuates the need for effective fatigue management in this patient 631 
population. In this setting, patients are likely to experience recurrent symptoms of fatigue, 632 
particularly following dialysis, and given the important role functioning-related factors 633 
appeared to play here; the focus of psychotherapy could revolve around reducing the impact 634 
of fatigue on functioning.  635 
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